Your browser doesn't support javascript.
loading
MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments.
Welsh, Joshua A; Van Der Pol, Edwin; Arkesteijn, Ger J A; Bremer, Michel; Brisson, Alain; Coumans, Frank; Dignat-George, Françoise; Duggan, Erika; Ghiran, Ionita; Giebel, Bernd; Görgens, André; Hendrix, An; Lacroix, Romaric; Lannigan, Joanne; Libregts, Sten F W M; Lozano-Andrés, Estefanía; Morales-Kastresana, Aizea; Robert, Stephane; De Rond, Leonie; Tertel, Tobias; Tigges, John; De Wever, Olivier; Yan, Xiaomei; Nieuwland, Rienk; Wauben, Marca H M; Nolan, John P; Jones, Jennifer C.
  • Welsh JA; Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Van Der Pol E; Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Arkesteijn GJA; Laboratory Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Bremer M; Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Brisson A; Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • Coumans F; Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Dignat-George F; UMR-5248-CBMN, CNRS-University of Bordeaux-IPB, Pessac, France.
  • Duggan E; Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Ghiran I; Laboratory Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Giebel B; Vesicle Observation Center, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Görgens A; Center of Cardiovascular Research and Nutrition (C2VN) UMR-INSERM INRA 1263, Aix-Marseille Université, INSERM, Marseille, France.
  • Hendrix A; Hematology and Vascular Biology Department, CHU La Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
  • Lacroix R; Scintillon Institute, San Diego, CA, USA.
  • Lannigan J; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Libregts SFWM; Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Lozano-Andrés E; Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Morales-Kastresana A; Clinical Research Center, Department for Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Robert S; Evox Therapeutics Ltd, Oxford, UK.
  • De Rond L; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University Hospital, Ghent, Belgium.
  • Tertel T; Center of Cardiovascular Research and Nutrition (C2VN) UMR-INSERM INRA 1263, Aix-Marseille Université, INSERM, Marseille, France.
  • Tigges J; Hematology and Vascular Biology Department, CHU La Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
  • De Wever O; Flow Cytometry Core, School of Medicine, University of Virginia, Charlottesville, VA, USA.
  • Yan X; Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • Nieuwland R; NIHR Cambridge BRC Cell Phenotyping Hub, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Wauben MHM; Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • Nolan JP; Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Jones JC; Evox Therapeutics Ltd, Oxford, UK.
J Extracell Vesicles ; 9(1): 1713526, 2020.
Article en En | MEDLINE | ID: mdl-32128070
Extracellular vesicles (EVs) are small, heterogeneous and difficult to measure. Flow cytometry (FC) is a key technology for the measurement of individual particles, but its application to the analysis of EVs and other submicron particles has presented many challenges and has produced a number of controversial results, in part due to limitations of instrument detection, lack of robust methods and ambiguities in how data should be interpreted. These complications are exacerbated by the field's lack of a robust reporting framework, and many EV-FC manuscripts include incomplete descriptions of methods and results, contain artefacts stemming from an insufficient instrument sensitivity and inappropriate experimental design and lack appropriate calibration and standardization. To address these issues, a working group (WG) of EV-FC researchers from ISEV, ISAC and ISTH, worked together as an EV-FC WG and developed a consensus framework for the minimum information that should be provided regarding EV-FC. This framework incorporates the existing Minimum Information for Studies of EVs (MISEV) guidelines and Minimum Information about a FC experiment (MIFlowCyt) standard in an EV-FC-specific reporting framework (MIFlowCyt-EV) that supports reporting of critical information related to sample staining, EV detection and measurement and experimental design in manuscripts that report EV-FC data. MIFlowCyt-EV provides a structure for sharing EV-FC results, but it does not prescribe specific protocols, as there will continue to be rapid evolution of instruments and methods for the foreseeable future. MIFlowCyt-EV accommodates this evolution, while providing information needed to evaluate and compare different approaches. Because MIFlowCyt-EV will ensure consistency in the manner of reporting of EV-FC studies, over time we expect that adoption of MIFlowCyt-EV as a standard for reporting EV- FC studies will improve the ability to quantitatively compare results from different laboratories and to support the development of new instruments and assays for improved measurement of EVs.
Palabras clave